Prognosis and Personalized Treatment Prediction in Different Mutation-Signature Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett. 2016;380(1):205–215. doi:10.1016/j.canlet.2015.07.044
   PubMed Web of Science ®Google Scholar
• Yang C, Huang X, Li Y, Chen J, Lv Y, Dai S. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology. Brief Bioinform. 2021;22(3). doi:10.1093/bib/bbaa164
   Web of Science ®Google Scholar
• Lachenmayer A, Alsinet C, Savic R, et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res. 2012;18(18):4997–5007. doi:10.1158/1078-0432.Ccr-11-2322
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang C, Liu W, Du X, Liu X, Xing B. Long noncoding RNA LINC01234 promotes hepatocellular carcinoma progression through orchestrating aspartate metabolic reprogramming. Mol Ther. 2022;30(6):2354–2369. doi:10.1016/j.ymthe.2022.02.020
   PubMed Web of Science ®Google Scholar
• Zhang C, Yang Y, Wang K, et al. The systematic analyses of RING finger gene signature for predicting the prognosis of patients with hepatocellular carcinoma. J Oncol. 2022;2022:2466006. doi:10.1155/2022/2466006
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013;3(1):246–259. doi:10.1016/j.celrep.2012.12.008
   PubMed Web of Science ®Google Scholar
• Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet. 2014;15(9):585–598. doi:10.1038/nrg3729
   PubMed Web of Science ®Google Scholar
• Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17(3):139–152. doi:10.1038/s41575-019-0229-4
   PubMed Web of Science ®Google Scholar
• Letouzé E, Shinde J, Renault V, et al. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nat Commun. 2017;8(1):1315. doi:10.1038/s41467-017-01358-x
   PubMedGoogle Scholar
• Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell. 2019;179(2):561–577.e22. doi:10.1016/j.cell.2019.08.052
   PubMed Web of Science ®Google Scholar
• Tamborero D, Gonzalez-Perez A, Lopez-Bigas N. OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics. 2013;29(18):2238–2244. doi:10.1093/bioinformatics/btt395
   PubMed Web of Science ®Google Scholar
• Ao L, Zhang Z, Guan Q, et al. A qualitative signature for early diagnosis of hepatocellular carcinoma based on relative expression orderings. Liver Int. 2018;38(10):1812–1819. doi:10.1111/liv.13864
   PubMed Web of Science ®Google Scholar
• Peng F, Wang R, Zhang Y, et al. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer. 2017;16(1):98. doi:10.1186/s12943-017-0666-z
   PubMedGoogle Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812–830.e14. doi:10.1016/j.immuni.2018.03.023
   PubMed Web of Science ®Google Scholar
• Liu Z, Xu H, Weng S, Ren Y, Han X. Stemness refines the classification of colorectal cancer with stratified prognosis, multi-omics landscape, potential mechanisms, and treatment options. Front Immunol. 2022;13:828330. doi:10.3389/fimmu.2022.828330
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang L, Guo C, et al. TTN/OBSCN ‘Double-Hit’ predicts favourable prognosis, ‘immune-hot’ subtype and potentially better immunotherapeutic efficacy in colorectal cancer. J Cell Mol Med. 2021;25(7):3239–3251. doi:10.1111/jcmm.16393
   PubMed Web of Science ®Google Scholar
• Liu Z, Liu L, Jiao D, et al. Association of RYR2 mutation with tumor mutation burden, prognosis, and antitumor immunity in patients with esophageal adenocarcinoma. Front Genet. 2021;12:669694. doi:10.3389/fgene.2021.669694
   PubMed Web of Science ®Google Scholar
• Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41. doi:10.1186/gb-2011-12-4-r41
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014;9(9):e107468. doi:10.1371/journal.pone.0107468
   PubMed Web of Science ®Google Scholar
• Ally A, Balasundaram M, Carlsen R, et al. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169(7):1327–1341.e23. doi:10.1016/j.cell.2017.05.046
   PubMed Web of Science ®Google Scholar
• Sun HC, Zhou J, Wang Z, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr. 2022;11(2):227–252. doi:10.21037/hbsn-21-328
   PubMed Web of Science ®Google Scholar
• Wu T, Luo G, Lian Q, et al. Discovery of a carbamoyl phosphate synthetase 1-deficient HCC subtype with therapeutic potential through integrative genomic and experimental analysis. Hepatology. 2021;74(6):3249–3268. doi:10.1002/hep.32088
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng XD, Zhu GQ, et al. Crosstalk between metabolism and immune activity reveals four subtypes with therapeutic implications in clear cell renal cell carcinoma. Front Immunol. 2022;13:861328. doi:10.3389/fimmu.2022.861328
   PubMed Web of Science ®Google Scholar
• Oh S, Yeom J, Cho HJ, et al. Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities. Nat Commun. 2020;11(1):3288. doi:10.1038/s41467-020-17139-y
   PubMed Web of Science ®Google Scholar
• Yang JC, Schuler M, Popat S, et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. J Thorac Oncol. 2020;15(5):803–815. doi:10.1016/j.jtho.2019.12.126
   PubMed Web of Science ®Google Scholar
• Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised Phase 3 trial. Lancet Oncol. 2015;16(5):583–594. doi:10.1016/s1470-2045(15)70124-5
   PubMed Web of Science ®Google Scholar
• Specenier P, Vermorken J. Afatinib in squamous cell carcinoma of the head and neck. Expert Opin Pharmacother. 2016;17(9):1295–1301. doi:10.1080/14656566.2016.1183647
   PubMed Web of Science ®Google Scholar
• Vengoji R, Macha MA, Nimmakayala RK, et al. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J Exp Clin Cancer Res. 2019;38(1):266. doi:10.1186/s13046-019-1264-2
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen X, Ding X, Wang Y. Afatinib, an EGFR inhibitor, decreases EMT and tumorigenesis of Huh‑7 cells by regulating the ERK‑VEGF/MMP9 signaling pathway. Mol Med Rep. 2019;20(4):3317–3325. doi:10.3892/mmr.2019.10562
   PubMed Web of Science ®Google Scholar
• Almalki SG, Agrawal DK. ERK signaling is required for VEGF-A/VEGFR2-induced differentiation of porcine adipose-derived mesenchymal stem cells into endothelial cells. Stem Cell Res Ther. 2017;8(1):113. doi:10.1186/s13287-017-0568-4
   PubMedGoogle Scholar
• Smaill JB, Rewcastle GW, Loo JA, et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem. 2000;43(7):1380–1397. doi:10.1021/jm990482t
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Morgan G, Ossenkoppele GJ, et al. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2010;28(28):4333–4338. doi:10.1200/jco.2009.27.6295
   PubMed Web of Science ®Google Scholar
• Harada K, Nishitsuji H, Ujino S, Shimotohno K. Identification of KX2-391 as an inhibitor of HBV transcription by a recombinant HBV-based screening assay. Antiviral Res. 2017;144:138–146. doi:10.1016/j.antiviral.2017.06.005
   PubMed Web of Science ®Google Scholar